Who is sponsoring NCT06062420?

NCT06062420 is sponsored by GlaxoSmithKline.

What condition does NCT06062420 study?

NCT06062420 studies Neoplasms, Head and Neck.

What drugs are being tested in NCT06062420?

Interventions: Dostarlimab, Belrestotug, Nelistotug, Remzistotug.

What is the status of NCT06062420?

NCT06062420 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2026-04-09 · How we verify

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420 PHASE2 ACTIVE_NOT_RECRUITING

The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	ACTIVE_NOT_RECRUITING
Enrolment	316
Start date	Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Neoplasms, Head and Neck

Interventions

Dostarlimab
Belrestotug
Nelistotug
Remzistotug

Countries

Italy, Finland, Japan, Taiwan, Poland, South Korea, Denmark, Portugal, United States, France, Greece, Hungary, Norway, Argentina, Canada, Romania, Spain, Brazil, Germany, Turkey (Türkiye)